Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Verici DxLSE:VRCI FCF Margin % is -278.29% as of Dec. 2025. The stock has 3 warning signs investors should review. Among 203 Medical Diagnostics & Research companies, Verici Dx ranks worse than 87.68% on this metric.
FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Verici Dx's Free Cash Flow for the
six
months ended in Dec. 2025 was £-3.64 Mil. Verici Dx's Revenue for the
six
months ended in Dec. 2025 was £1.31 Mil. Therefore, Verici Dx's FCF Margin % for the quarter that ended in Dec. 2025 was -278.29%.
The historical rank and industry rank for Verici Dx's FCF Margin % or its related term are showing as below:
LSE:VRCI'
s FCF Margin % Range Over the Past 10 Years
Min: -729.75 Med: -230.73 Max: -186.1
Current: -231.05
During the past 6 years, the highest FCF Margin % of Verici Dx was -186.10%. The lowest was -729.75%. And the median was -230.73%.
LSE:VRCI's FCF Margin % is ranked worse than 87.68% of 203
companies
in the Medical Diagnostics & Research industry
Industry Median: -1.8
vs LSE:VRCI: -231.05
Verici Dx FCF Margin % Related Terms
Verici Dx FCF Margin % Historical Data
* Premium members only.
The historical data trend for Verici Dx's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LSE:VRCI vs TMO, DHR, IDXX: FCF Margin % Comparison
For the Diagnostics & Research subindustry, Verici Dx's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Verici Dx FCF Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Verici Dx's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Verici Dx's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Verici Dx (LSE:VRCI) has a FCF Margin % of -278.29% as of Dec. 2025. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Verici Dx and its competitors. According to the industry distribution chart, Verici Dx ranks #178 out of 203 companies in the Medical Diagnostics & Research industry, placing it in the top 87.7%.
Is Verici Dx's FCF Margin % too high?
Verici Dx's current FCF Margin % is -278.29%. Based on the distribution chart, Verici Dx ranks #178 out of 203 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers.
How does Verici Dx's FCF Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Verici Dx ranks #178 out of 203 companies for FCF Margin %. This places Verici Dx in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Medical Diagnostics & Research company?
A good FCF Margin % depends on the Medical Diagnostics & Research industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Verici Dx and its competitors. Verici Dx's current FCF Margin % is -278.29%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Verici Dx stock overvalued right now?
Verici Dx (LSE:VRCI) has a current FCF Margin % of -278.29%. The current FCF Margin % is -278.29%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Verici Dx (LSE:VRCI), the current FCF Margin % is -278.29% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Verici Dx PLC is an immuno-diagnostics development company. The company is focused on the development of prognostic and diagnostic tests for kidney transplant patients. There are two products for clinical validation and commercialization: Clarava, which is a pre-transplant prognosis for the risk of early acute rejection; Tuteva, a post-transplant diagnostic focused upon acute cellular rejection, including sub-clinical rejection not being diagnosed through the current standard of care of rising serum creatine levels; and Protega will utilize RNA gene signatures to more accurately risk stratify outcome from fibrosis in a transplant patient. The business of the Group comprises a single activity, which of the development of prognostic and diagnostic tests for kidney transplant patients.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:VRCI has been successfully added to your 
